Patents Assigned to Rohto Pharmaceutical Co., Ltd.
-
Patent number: 9034931Abstract: This invention relates to an aqueous ophthalmic composition comprising (A) polyoxyethylene castor oil in which the average number of moles of added ethylene oxide is 2 to 12 and (B) terpenoid. According to the present invention, an aqueous ophthalmic composition having an improved foam disappearance speed can be obtained.Type: GrantFiled: December 27, 2011Date of Patent: May 19, 2015Assignee: ROHTO PHARMACEUTICAL CO., LTD.Inventors: Chinatsu Furumiya, Takayuki Miyano, Atsuko Nakata, Eri Matsumoto
-
Publication number: 20150064281Abstract: The present invention provides an ophthalmic composition containing (A) a biguanide-based disinfectant and (B) zinc chloride. According to the present invention, an ophthalmic composition having remarkably increased disinfection effects against Acanthamoeba is provided.Type: ApplicationFiled: April 4, 2013Publication date: March 5, 2015Applicant: ROHTO PHARMACEUTICAL CO., LTD.Inventors: Kazuhiro Fukushima, Mariyo Kato, Yoshihiro Takai, Masashi Itoh
-
Publication number: 20150018416Abstract: The present invention relates to an aqueous ophthalmic composition comprising (A) polyoxyethylene castor oil, (B) polyethylene glycol monostearate, and (C) at least one member selected from the group consisting of sesame oil, castor oil, vitamin A, and chlorobutanol.Type: ApplicationFiled: November 29, 2013Publication date: January 15, 2015Applicant: ROHTO PHARMACEUTICAL CO., LTD.Inventors: Ryo Komurasaki, Yoko Mizutare, Atsuko Nakata
-
Publication number: 20140302146Abstract: The present invention provides an ophthalmic aqueous composition having an oil-in-water emulsion including a vegetable oil, a non-ionic surfactant, and a terpenoid, wherein an average particle diameter of emulsion particles is within the range of 30 nm to 300 nm.Type: ApplicationFiled: July 5, 2012Publication date: October 9, 2014Applicant: ROHTO PHARMACEUTICAL CO.,LTD.Inventors: Takahiro Kurose, Takayuki Miyano, Toru Okubo, Mariyo Kato
-
Publication number: 20140243419Abstract: Application of a pharmaceutical preparation comprising geranylgeranylacetone to the mucosa of, for example, the eye, nose, oral cavity or pharynx can efficiently prevent, ameliorate or treat retinal diseases such as glaucoma, retinitis pigmentosa, age-related macular degeneration, and diabetic retinopathy.Type: ApplicationFiled: May 1, 2014Publication date: August 28, 2014Applicant: ROHTO PHARMACEUTICAL CO., LTD.Inventors: Takahiro KUROSE, Yoshihiro TAKAI, Takayuki MIYANO, Yusuke TAKEUCHI
-
Patent number: 8754029Abstract: The present invention provides an ophthalmic composition which stabilizes the tear film during wearing contact lens, prevents eye dryness, imparts a favorable sensation in using, is highly convenient with no risk of misuse and shows a high efficiency in the course from manufacturing to sales. More specifically, the present invention provides a wetting solution—eye drops for contact lenses comprising (A) one or more member(s) selected from the group consisting of a cellulose-based polymer, a vinyl-based polymer, polyethylene glycol and dextran; and (B) a terpenoid.Type: GrantFiled: November 15, 2012Date of Patent: June 17, 2014Assignee: Rohto Pharmaceutical Co., Ltd.Inventors: Yasuko Matsumura, Kazuhiro Fukushima
-
Patent number: 8727651Abstract: An elevating container includes an elliptically shaped main tube, a non-circularly shaped moveable support unit which moves upwardly or downwardly along an inner surface of a storage tube of the main tube without rotating, and a driving unit fitted to the main tube to rotate in threaded engagement to the support unit without moving upwardly or downwardly. A seal section at the lower end of the inner peripheral surface of the storage tube and a sealing cylinder at the lower end of the support unit are air-tightly fitted to each other. In addition, positioning ribs are provided at the lower end of the storage tube, and positioning notches are provided at the lower end of the moveable support unit. When the positioning ribs and the positioning notches are engaged with each other, a circumferential misalignment between the main tube and the support unit is corrected.Type: GrantFiled: February 3, 2009Date of Patent: May 20, 2014Assignees: Rohto Pharmaceutical Co., Ltd., Yoshino Kogyosho Co., LtdInventors: Ken Arai, Takamitsu Okawara, Masakazu Mameta, Tsutomu Kobayashi, Hideo Uemura
-
Publication number: 20140128475Abstract: A prophylactic, ameliorating or therapeutic agent for a retinal disease, the agent comprising geranylgeranylacetone which (a) is a mixture of (5E,9E,13E)-geranylgeranylacetone and (5Z,9E,13E)-geranylgeranylacetone, the (5E,9E,13E)-geranylgeranylacetone content of the mixture being 80% by weight or more, (b) consists of (5E,9E,13E)-geranylgeranylacetone, or (c) consists of (5Z,9E,13E)-geranylgeranylacetone directly suppresses the death of a retinal cell, thereby fundamentally preventing, ameliorating or treating the retinal disease.Type: ApplicationFiled: January 14, 2014Publication date: May 8, 2014Applicant: ROHTO PHARMACEUTICAL CO., LTD.Inventors: Takahiro KUROSE, Takayuki MIYANO, Mariyo KATO, Yoshihiro TAKAI
-
Patent number: 8669241Abstract: The ophthalmic composition of the invention comprises (A) lecithin and (B) at least one refrigerant selected from the group consisting of camphor, borneol, eucalyptus oil, and bergamot oil. In the ophthalmic composition, the odor of lecithin is efficiently masked by the refrigerant. The odor of lecithin after aging is also masked by the refrigerant. Since the refrigerant is volatile, the concentration thereof in a composition tends to gradually decrease. It is surprising that the odor of lecithin after aging can nevertheless be masked.Type: GrantFiled: December 1, 2009Date of Patent: March 11, 2014Assignee: Rohto Pharmaceutical Co., Ltd.Inventors: Yasuko Matsumura, Mariyo Kato
-
Publication number: 20140045948Abstract: An ophthalmic composition kit comprising an ophthalmic container holding an ophthalmic composition comprising geranylgeranylacetone, the ophthalmic container having a surface in contact with the ophthalmic composition, the surface being at least partially or wholly made of a container material selected from the group consisting of a polyolefin, an acrylic acid resin, a terephthalic acid ester, a polycarbonate, a polymethylterpene, a fluorine resin and a glass, the ophthalmic composition kit having an advantage that the loss of the geranylgeranylacetone content or decrease in the geranylgeranylacetone concentration in the ophthalmic composition is very little.Type: ApplicationFiled: October 17, 2013Publication date: February 13, 2014Applicant: ROHTO PHARMACEUTICAL CO., LTD.Inventors: Takayuki MIYANO, Takahiro KUROSE
-
Publication number: 20140005277Abstract: This invention relates to an aqueous ophthalmic composition comprising (A) polyoxyethylene castor oil and (B) sesame oil. According to the aqueous ophthalmic composition of the present invention, defoaming time is reduced, preservative efficacy is enhanced and photostability is improved.Type: ApplicationFiled: December 19, 2012Publication date: January 2, 2014Applicant: ROHTO PHARMACEUTICAL CO., LTD.Inventors: Atsuko NAKATA, Eri MATSUMOTO
-
Publication number: 20140005274Abstract: This invention relates to an aqueous ophthalmic composition comprising (A) polyoxyethylene castor oil in which the number of moles of added ethylene oxide is 2 to 30, and (B) at least one member selected from the group consisting of castor oil and vitamin A. According to the aqueous ophthalmic composition of the present invention, the defoaming time can be reduced even when foam is generated by vibration or impact.Type: ApplicationFiled: December 19, 2012Publication date: January 2, 2014Applicant: ROHTO PHARMACEUTICAL CO., LTD.Inventor: Atsuko NAKATA
-
Publication number: 20130331458Abstract: An ophthalmic composition kit comprising an ophthalmic container holding an ophthalmic composition comprising geranylgeranylacetone, the ophthalmic container having a surface in contact with the ophthalmic composition, the surface being at least partially or wholly made of a container material selected from the group consisting of a polyolefin, an acrylic acid resin, a terephthalic acid ester, a polycarbonate, a polymethylterpene, a fluorine resin and a glass, the ophthalmic composition kit having an advantage that the loss of the geranylgeranylacetone content or decrease in the geranylgeranylacetone concentration in the ophthalmic composition is very little.Type: ApplicationFiled: February 25, 2013Publication date: December 12, 2013Applicant: ROHTO PHARMACEUTICAL CO., LTD.Inventor: ROHTO PHARMACEUTICAL CO., LTD.
-
Publication number: 20130296446Abstract: This invention relates to an aqueous ophthalmic composition comprising (A) polyoxyethylene castor oil in which the average number of moles of added ethylene oxide is 2 to 12 and (B) terpenoid. According to the present invention, an aqueous ophthalmic composition having an improved foam disappearance speed can be obtained.Type: ApplicationFiled: December 27, 2011Publication date: November 7, 2013Applicant: ROHTO PHARMACEUTICAL CO., LTD.Inventors: Chinatsu Furumiya, Takayuki Miyano, Atsuko Nakata, Eri Matsumoto
-
Publication number: 20130274332Abstract: An object of the present invention is to provide an ophthalmic composition for contact lens that can inhibit bacterial adhesion to a contact lens. The ophthalmic composition for contact lens can be prepared by using a combination of (A) polyoxyethylene castor oil and (B) terpenoid.Type: ApplicationFiled: December 15, 2011Publication date: October 17, 2013Applicant: ROHTO PHARMACEUTICAL CO., LTD.Inventors: Chinatsu Furumiya, Atsuko Nakata
-
Publication number: 20130244978Abstract: The present invention provides an ophthalmic composition which stabilizes the tear film during wearing contact lens, prevents eye dryness, imparts a favorable sensation in using, is highly convenient with no risk of misuse and shows a high efficiency in the course from manufacturing to sales. More specifically, the present invention provides a wetting solution—eye drops for contact lenses or an ophthalmic composition/solution for contact lenses, which comprises (A) one or more member(s) selected from the group consisting of a cellulose-based polymer, a vinyl-based polymer, polyethylene glycol and dextran; and (B) a terpenoid.Type: ApplicationFiled: May 8, 2013Publication date: September 19, 2013Applicant: ROHTO PHARMACEUTICAL CO., LTD.Inventors: Yasuko MATSUMURA, Kazuhiro FUKUSHIMA
-
Publication number: 20130210921Abstract: A method for giving warmth to skin, wherein an external composition for skin is provided, which gives good warmth without inducing irritation or pain and whose sustainability of warmth is good. The external composition for skin contains (A) an agent for giving warmth and (B) at least one member selected from the group consisting of fatty acid esters of aliphatic polyhydric alcohols and aromatic carboxylic acid esters of lower alcohols or aliphatic polyhydric alcohols.Type: ApplicationFiled: February 14, 2013Publication date: August 15, 2013Applicant: ROHTO PHARMACEUTICAL CO., LTD.Inventor: ROHTO PHARMACEUTICAL CO., LTD.
-
Patent number: 8501822Abstract: An ophthalmic composition that, despite containing alginic acid and/or a salt thereof, has improved tackiness during use and provides a satisfactory use feeling. The composition has an improved ability to remain on the eye mucosa. The ophthalmic composition contains (A) alginic acid and/or a salt thereof in combination with (B) hyaluronic acid and/or a salt thereof.Type: GrantFiled: March 27, 2012Date of Patent: August 6, 2013Assignee: Rohto Pharmaceutical Co., Ltd.Inventors: Eri Matsumoto, Yasuko Nishina, Kenichi Haruna, Harumasa Arita, Akiko Kita
-
Publication number: 20130102977Abstract: The present invention provides an ophthalmic composition which stabilizes the tear film during wearing contact lens, prevents eye dryness, imparts a favorable sensation in using, is highly convenient with no risk of misuse and shows a high efficiency in the course from manufacturing to sales. More specifically, the present invention provides a wetting solution—eye drops for contact lenses comprising (A) one or more member(s) selected from the group consisting of a cellulose-based polymer, a vinyl-based polymer, polyethylene glycol and dextran; and (B) a terpenoid.Type: ApplicationFiled: November 15, 2012Publication date: April 25, 2013Applicant: ROHTO PHARMACEUTICAL CO., LTD.Inventor: ROHTO PHARMACEUTICAL CO., LTD.
-
Publication number: 20120238519Abstract: An ophthalmic composition that, despite containing alginic acid and/or a salt thereof, has improved tackiness during use and provides a satisfactory use feeling. The composition has an improved ability to remain on the eye mucosa. The ophthalmic composition contains (A) alginic acid and/or a salt thereof in combination with (B) hyaluronic acid and/or a salt thereof.Type: ApplicationFiled: March 27, 2012Publication date: September 20, 2012Applicant: ROHTO PHARMACEUTICAL CO., LTD.Inventors: Eri MATSUMOTO, Yasuko NISHINA, Kenichi HARUNA, Harumasa ARITA, Akiko KITA